IP Library Granted Patent US 10,065,920
Granted Patent B2
US 10,065,920 · App. 15/885,387 · Granted Sep 4, 2018

Crystalline solid forms of the acetate salt of (1S,3S,4R)-4-((3AS,4R,5S,7AS)-4-(aminomethyl)-7A-methyl-1-methyleneoctahydro-1H-inden-5-YL)-3- (hydroxymethyl)-4-methylcyclohexanol

Inventors: Lloyd F. Mackenzie (North Vancouver, CA); Jeffery R. Raymond (Vancouver, CA); Curtis Harwig (Vancouver, CA); Ana Fernandez Casares (Amsterdam, NL)
Assignee: Aquinox Pharmaceuticals (Canada) Inc.
C07C215/42C07B2200/13C07C2601/14C07C2602/08C07C2602/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,065,920
App. No.
15/885,387
Granted
Sep 4, 2018
Kind
B2
Abstract

The present invention is generally directed to novel crystalline forms of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol and processes for their preparation.

Claims (8)

1. A crystalline form of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol, designated as Compound 1 Form B, characterized by an X-ray powder diffraction pattern containing the following peaks: 5.5, 9.4 and 12.2 degrees 2Θ±0.3 degrees 2Θ.

2. The crystalline form of claim 1 further characterized by an X-ray powder diffraction pattern containing one or more of the following additional peaks: 9.0, 12.2, 12.9, 13.2, 14.0, 14.3, 15.4, 16.1, 16.6, 17.0, 18.0, 18.3, 19.0, 20.0, 21.3, 22.8, 24.4, 25.0, 25.8, 26.8, 27.3, 28.1, 28.9, 31.1, 32.5, 33.5, 34.3 and 36.3 degrees 2Θ±0.3 degrees 2Θ.

3. The crystalline form of claim 1 characterized by a DSC with an endothermic event with an onset at 170.4° C.±0.3° C. and a characterizing endothermic peak at 186.6° C.±0.3° C.

4. The crystalline form of claim 1 characterized by one or more of:

XRPD pattern substantially set out in Table 5 and/or FIG. 10 ;

DSC thermogram substantially set out in FIG. 11 ; and

TGA thermogram substantially set out in FIG. 12 .

5. A method for preparing the crystalline form of claim 1 comprising the steps of mixing the amorphous form of the acetate salt of (1S,3S,4R)-4-((3aS,4R,5S,7aS)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1H-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol with solvents of mixtures thereof selected from the group consisting of water and tetrahydrofuran.

Assignments (4)
MERGER Recorded Dec 13, 2021
From: TARO PHARMACEUTICALS INC.; AQUINOX PHARMACEUTICALS (CANADA) INC.
To: TARO PHARMACEUTICALS INC.
Reel/Frame 058371/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: MACKENZIE, LLOYD F.; RAYMOND, JEFFERY R.; HARWIG, CURTIS
To: AQUINOX PHARMACEUTICALS (CANADA) INC.
Reel/Frame 045742/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: FERNANDEZ CASARES, ANA
To: CRYSTALLICS BV
Reel/Frame 045742/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2018
From: CRYSTALLICS BV
To: AQUINOX PHARMACEUTICALS (CANADA) INC.
Reel/Frame 045742/0895 →
Continuity (3)
Division 15191134 · Jun 23, 2016
Provisional Application 62185416 · Jun 26, 2015
Related Publication 20180155273A1 · Jun 7, 2018